Neurotrophin-3 gene therapies and compositions and uses thereof
The rAAV particle delivering NT-3 to Schwann cells addresses the lack of effective treatments for CMT1A by enhancing neurotrophin-3 production, improving nerve and muscle function.
Patent Information
- Application Number
- PCT/US2026/027686
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for Charcot-Marie-Tooth disease (CMT1A) are limited to supportive care, lacking an effective broad-spectrum therapy to ameliorate physical symptoms such as muscle weakness and atrophy.
A recombinant adeno-associated virus (rAAV) particle containing a payload nucleotide sequence encoding human NT-3 polypeptide, packaged in an AAVrh74 capsid, is used to deliver the NT-3 gene to Schwann cells, promoting myelination and nerve function.
The rAAV particle effectively increases neurotrophin-3 protein levels in cells, potentially reversing nerve damage and improving muscle function in CMT1A patients.
Smart Images

Figure US2026027686_19112026_PF_FP_ABST
Abstract
Description
Atty Docket No. 140056-10122025-039-02; 8216. WO01NEUROTROPHIN-3 GENE THERAPIES AND COMPOSITIONS AND USES THEREOFCROSS-REFERENCE TO RELATED PATENT APPLICATION
[0001] This application claims the benefit under 35 U. S. C. § 119(e) of U. S. Provisional Application No. 63 / 804,470, filed May 12, 2025, the entire contents of which are incorporated herein by reference.FIELD OF DISCLOSURE
[0002] The present disclosure pertains to the medical field including gene therapy, for example, the treatment of diseases (e.g., neuromuscular disorders) by gene therapy.BACKGROUND
[0003] Charcot-Marie-Tooth (CMT) Disease, historically known as Hereditary Motor and Sensory Neuropathy (HMSN), is the most common inherited peripheral neuropathy with a reported prevalence of 1:2500.1 The disease is divided into subtypes based on the inheritance pattern, genetic cause, and pathogenic mechanisms focusing primarily on either denervation or demyelination. CMT1A is the most prevalent subtype and is defined by a duplication of the chromosome containing the gene for peripheral myelin protein 22 (PMP22).2 Over time, the overexpression of PMP22 in Schwann cells, the myelinating cells of the peripheral nervous system, leads to weakening of the cells and eventually causes Schwann cell death (Li, J., et al. Mol Neurobiol 2013, 47 (2), 673-698.). The reduction of myelination and eventual loss of myelinating capabilities in peripheral nerves results in slowed nerve conduction velocities and lowered nerve impulse signal, leading to muscle weakness and atrophy (Morena, J., et al. Int J Mol Sci 2019, 20 (14). DOI: 10.3390 / ijms20143419).
[0004] CMT1A patients typically present symptoms in the first two decades of life with difficulty walking or running. Distal muscle weakness and atrophy as well as sensory loss presents in a length-dependent manner, impacting the feet first and progressing proximally with legs more frequently and severely affected than arms. Hallmark features of CMT1 A include pes cavus (high arch foot deformity) with hammertoes and a “stork appearance” of the legs due to symmetrical muscle weakness and wasting. Proprioceptive loss causing balance difficulties and decreased14924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 manual dexterity are also hallmarks of the disease (98-118. DOI: 10.1111 / j.1399-0004.1974.tb00638). Pain is a common symptom of CMT1A patients but is typically moderate, with limited impact on daily life (Ribiere, C., et al. Ann Phys Rehabil Med 2012, 55 (3), 160-173. DOI: 10.1016 / j. rehab.2012.02.005). CMT1A patients exhibit normal life expectancy, however physical disability increases as the disease progresses (Verhamme, C, et al. Brain 2009, 132 (Pt 12), 3252-3262. DOI: 10.1093 / brain / awp251.).
[0005] Treatment options for CMT, as with several similar demyelination-related conditions, are currently limited to supportive care. An effective, broad-spectrum treatment to ameliorate the physical symptoms of CMT subtypes and related disorders is desperately needed.BRIEF SUMMARY
[0006] In some aspects, provided herein is a recombinant adeno-associated virus (rAAV) particle comprising a payload nucleotide sequence which comprises the payload nucleotide sequence as set forth in SEQ ID NO: 8 and an AAVrh74 capsid protein comprising the amino acid sequence set forth in SEQ ID NO: 9.
[0007] In some aspects provided herein is a rAAV particle comprising a capsid protein and a payload nucleotide sequence, wherein the payload nucleotide sequence comprises a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1, a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2, an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3, a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5, an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6, and a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7 and wherein the capsid protein comprises an AAVrh74 capsid protein as set forth in SEQ ID NO: 9, or a variant thereof. In some aspects, the rAAV particle comprises a payload nucleotide sequence that has at least 95% sequence identity to SEQ ID NO: 8. In some aspects, the rAAV particle comprises a payload nucleotide sequence that has at least 99% sequence identity to SEQ ID NO: 8. In some aspects, the rAAV particle comprises the payload nucleotide sequence set forth in SEQ ID NO: 8. In some aspects, the rAAV particle comprises a pharmaceutically acceptable carrier.
[0008] In some aspects, provided herein is an expression cassette comprising the nucleotide sequence set forth in SEQ ID NO: 8. In some aspects, the expression cassette comprises a MCK24924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2, an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3, a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5, and an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6. In some aspects, disclosed herein is a vector comprising an expression cassette described above. In some aspects, the vector is an AAV vector. In some aspects, the vector further comprises a nucleotide sequence encoding a first inverted terminal repeat (ITR) and a second ITR. In some aspects, the first ITR is at the 5' of a payload nucleotide sequence and a second ITR is at the 3' of a payload nucleotide sequence. In some aspects, the first and the second ITR are of a same or of different serotypes. In some aspects, serotype of the ITRs is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAVrhlO, AAVrh74, AAV11, or AAV12 serotype. In some aspects, the first ITR comprises a nucleotide sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1. In some aspects, the second ITR comprises a nucleotide sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 7. In some aspects, the vector further comprises a nucleotide sequence encoding a selectable marker. In some aspects, provided herein is a pharmaceutical formulation comprising a previously described rAAV particle, expression cassette, vector, or any combination thereof and at least one pharmaceutically acceptable carrier.
[0009] In some aspects, provided herein is a nucleic acid comprising a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO: 12 (pAAV.tMCK. NT3. KAN). In some aspects, the nucleic acid comprises a nucleotide sequence has at least 99% sequence identity to SEQ ID NO: 12. In some aspects, the nucleic acid comprises a nucleotide sequence set forth in SEQ ID NO: 12. In some aspects, provided herein is a cell that comprises a previously described nucleic acid. In some aspects, the cell is a packaging cell. In some aspects, the cell is selected from a HeLa cell, a human fetal kidney cell (HEK293 cell), a PerC6 cell, a human fetal fibroblast cell (MRC-5 cell), a human fetal fibroblast cell (WI-38 cell), a monkey kidney cell (Vero cell) and a rhesus fetal lung cell (FRhL-2 cell), or any combination thereof. In some aspects, provided herein is a method of manufacturing an infectious recombinant AAV (rAAV) particle, the method comprising contacting a previously described nucleic acid to a mammalian cell. In some aspects,34924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 the method further comprises purification of the infectious rAAV particle. In some aspects, the infectious rAAV particle serotype is AAVrh74. In some aspects, a purified rAAV particle is prepared by a previously described method.
[0010] In some aspects, provided herein is a method of increasing the amount of functional neurotrophin-3 protein in a cell comprising contacting the cell with a previously described rAAV particle, expression cassette, vector, pharmaceutical formulation, or any combination thereof. In some aspects, the cell is a muscle cell. In some aspects, the cell is a neuron. In some aspects, the cell is a human cell.BRIEF DESCRIPTION OF DRAWINGS
[0011] FIGs.lA, IB, and 1C collectively illustrate overviews of the various stages of gene therapy vector production, including (A) upstream processing, (B) harvesting, and (C) downstream processing.
[0012] FIGs.lA, IB, and 2C collectively show the results of AAV1 and AAVrh74 vector production, including (FIG.2A) viable cell density (VCD), (FIG.2B) secreted viral genome (VG) titer, and (FIG. 2C) total VG following of the bulk drug substance (BDS).
[0013] FIGs. 3A and 3B show (FIG.3A) detection of NT-3 and (FIG. 3B) normalization to GAPDH following in vitro transduction with the indicated vector at the indicated multiplicity of infection (MOI).
[0014] FIG. 4 shows Circulating NT-3 Levels in wildtype (C57BL / 6J) mice after 4 weeks treatment with either AAV1. NT3 or AAVrh74 determined by ELISA.
[0015] FIGs. 5A, 5B and 5C show biodistribution of AAVrh74. NT3 in (FIG. 5A) left gastrocnemius (LGAS), (FIG. 5B) serum, and (FIG. 5C) other tissues — kidney (KID), brain (BRN), dorsal root ganglia (DRG), and thoracic spinal cord (SCT). Values represent mean ± SEM with individual values shown. Statistics for (FIG. 5A) and (FIG. 5B) are shown against the IM injection group. Statistics were run but not graphically represented for the tissues in Panel C. **p<0.01, ***p<0.001, ****p<0.0001.
[0016] FIGs. 6A and 6B collectively show expression of mature NT-3 protein in (FIG.6A) right gastrocnemius muscle (RGAS) and (FIG. 6B) heart muscle. Values represent mean ± SEM with individual values shown. Statistical comparisons are shown against the IM injection group. *p<0.05, ****p<0.0001.44924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01
[0017] FIG. 7 shows circulating NT-3 levels as determined by MSD. Statistical comparisons were run but not represented graphically. Values represent mean ± SEM with individual values shown.DETAILED DESCRIPTION OF THE DISCLOSURE
[0018] In some aspects, disclosed herein are polynucleotides (e.g., expression cassettes) encoding such one or more therapeutic polypeptides; vectors comprising such polynucleotides (e.g., AAV vectors comprising such expression cassettes); methods of making those vectors; recombinant AAV (rAAV) particles comprising such vectors; pharmaceutical compositions comprising the polynucleotides, the vectors, and / or the rAAV particles disclosed herein; and methods of using the polynucleotides, the vectors, the rAAV particles, and / or the pharmaceutical compositions disclosed herein.Definitions
[0019] In order that the present disclosure can be more readily understood, certain terms are first defined. As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety.
[0020] The practice of the present technology will employ, unless otherwise indicated, conventional techniques of tissue culture, immunology, molecular biology, microbiology, cell biology, and recombinant DNA, which are within the skill of the art.
[0021] Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination. Moreover, the disclosure also contemplates that in some embodiments, any feature or combination of features set forth herein can be excluded or omitted. To illustrate, if the specification states that a complex comprises components A, B and C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or in any combination.54924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01
[0022] Unless explicitly indicated otherwise, all specified embodiments, features, and terms intend to include both the recited embodiment, feature, or term and biological equivalents thereof.
[0023] All numerical designations, e.g., pH, temperature, time, concentration, and molecular weight, including ranges, are approximations which are varied (+) or (-) by increments of 1.0 or 0.1, as appropriate, or alternatively by a variation of + / - 15 %, or alternatively 10%, or alternatively 5%, or alternatively 2% and such ranges are included. It is to be understood, although not always explicitly stated, that all numerical designations are preceded by the term “about”. It also is to be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents of such are known in the art.
[0024] It is to be noted that, as used herein, the indefinite articles "a" or "an" should be understood to refer to "one or more" of any recited or enumerated component; for example, "a nucleic acid sequence," is understood to represent one or more nucleic acid sequences, unless stated otherwise. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein. The use of the alternative (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives.
[0025] Furthermore, "and / or", where used herein, is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and / or" as used in a phrase such as " A and / or B" herein is intended to include " A and B," " A or B," " A" (alone), and " B" (alone). Likewise, the term "and / or" as used in a phrase such as " A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0026] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of' and / or "consisting essentially of' are also provided.
[0027] As used herein, the term "about" refers to a value that is within 10% above or below the value being described.
[0028] The term "at least" prior to a value or series of values is understood to include the values adjacent to the term "at least," and all subsequent values (numbers, integers, or fractions) that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer, e.g., "at least 18 nucleotides of a 21- nucleotide nucleic acid molecule" means that 18, 19, 20, or 21 nucleotides have the indicated property. When "at64924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 least" is present before a series of numbers or a range, it is understood that "at least" can modify each of the numbers in the series or range. " At least" is also not limited to integers (e.g., "at least 5%" includes 5.0%, 5.1%, 5.18% without consideration of the number of significant figures).
[0029] As used herein, "no more than" or "less than" is understood as the value adjacent to the phrase and logical lower values (numbers, integers, or fractions), as logical from context, to zero. When "no more than" is present before a series of values or a range, it is understood that "no more than" can modify each of the value in the series or range.
[0030] As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.
[0031] The term "derived from," as used herein, refers to a component that is isolated from or made using a specified molecule or organism, or information (e.g., amino acid or nucleic acid sequence) from the specified molecule or organism.
[0032] " Nucleic acid," "polynucleotide," and "oligonucleotide," are used interchangeably in the present application. These terms refer only to the primary structure of the molecule. Thus, these terms include double- and single-stranded DNA, as well as double- and single-stranded RNA e.g., messenger RNAs (mRNAs), genomic DNAs, plasmid DNAs (pDNAs), or complementary DNAs (cDNAs)). The terms "nucleic acid," "polynucleotide," and "oligonucleotide," as used herein, are defined as it is generally understood by the person skilled in the art as a molecule comprising two or more covalently linked nucleosides. Such covalently bound nucleosides can also be referred to as nucleic acid molecules or oligomers. Polynucleotides can be made recombinantly, enzymatically, or synthetically, e.g., by solid-phase chemical synthesis followed by purification. When referring to a sequence of the polynucleotide or nucleic acid, reference is made to the sequence or order of nucleobase moieties, or modifications thereof, of the covalently linked nucleotides or nucleosides.
[0033] As used herein, the term "nucleotide" refers to monomeric units of nucleic acid polymers (e.g., deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)). Naturally occurring nucleotides are composed of three subunit molecules: a nucleobase, a five-carbon sugar (ribose or deoxyribose), and phosphate group consisting of one to three phosphates. A nucleotide can also be a modified nucleotide, which is a nucleotide comprising a modified nucleobase, a modified sugar moiety, a modified backbone, or any combination thereof. As used herein, the term "nucleobases",74924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 also known as "nitrogenous bases" or "bases", refers to biological compounds that form nucleosides, which, in turn, are components of nucleotides. A "nucleoside" comprises a nucleobase and a sugar moiety. A "sugar moiety" may comprise ribose or deoxyribose, as present in naturally occurring nucleotides. As used herein, the term "backbone," and "backbone structure", refer to the connection between monomers of a nucleic acid. In naturally occurring oligonucleotides, the backbone comprises a 3 '-5' phosphodiester linkage connecting sugar moi eties of the oligomer.
[0034] As used herein, the term "coding sequence" or a sequence "encoding" refers to a particular molecule which is a nucleic acid that is transcribed (in the case of DNA) or translated (in the case of RNA) into protein, in vitro or in vivo, when operably linked to an appropriate regulatory sequence, such as a promoter. The boundaries of the coding sequence are determined by a start codon at the 5 ' (amino) terminus and a translation stop codon at the 3 ' (carboxy) terminus. Although a "stop codon" (e.g., TAG, TGA, or TAA) is not translated into an amino acid, it can be considered to be part of a coding region, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, and the like, are not part of a coding region. A coding sequence can include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and synthetic DNA sequences. A transcription termination sequence will usually be located 3' to the coding sequence.
[0035] As used herein, the term "exon" refers to coding sections of a DNA molecule, or of an RNA molecule which is transcribed from a DNA molecule that are translated into protein. Exons can be separated by intervening sections of DNA that do not code for proteins, known as "introns". Therefore, the term "intron", as used herein, refers to a segment of nucleic acid that is transcribed and is present in the "pre-mRNA" but excised by the splicing machinery and therefore not present in the mature mRNA transcript. Following transcription, new, immature strands of messenger RNA, called "pre-mRNA", may contain both introns and exons. These pre-mRNA molecules go through a modification process in the nucleus called splicing during which the noncoding introns are cut out and only the coding exons remain in the "mature mRNA". Splicing produces a mature messenger RNA molecule that is then translated into a protein. The term "first exon" refers to a coding sequence or sequence of nucleic acid that encodes a polypeptide or polypeptide region and the term "second exon" refers to a different second coding sequence or sequence of nucleic acid that encodes a second polypeptide region. Where the two exons are separated by an intervening84924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 intron in the pre-mRNA, the splicing machinery operates to remove the intervening intron and join the two exons in the mature mRNA.
[0036] The term "polyadenylation signal" refers to a nucleic acid sequence present in the RNA transcript that allows for the transcript, when in the presence of the enzyme polyadenyl transferase, to be polyadenylated.
[0037] The term "promoter," as used herein in, refers to a sequence sufficient to direct transcription, in a cell. A promoter is intended as a DNA region to which RNA polymerases bind and that directs the enzyme to transcribe an operably linked DNA sequence. A DNA sequence is operably linked to a promoter if the promoter is capable of directing transcription of that DNA sequence. Promoters for use in the invention include prokaryotic, eukaryotic (e.g., mammalian or yeast), and viral promoters, e.g., the CMV (mammalian cytomegalovirus) promoter, the CAG promoter (also known as CBA promoter; CMV early enhancer / chicken P actin promoter), the UbC (polyubiquitin C gene) promoter, or the CBh (an engineered CBA promoter in which the SV40 intron is replaced with a hybrid intron composed of a 5' donor splice site from the chicken P-actin 5' UTR and a 3' acceptor splice site from MVM). A promoter can be a "constitutive" promoter that is a promoter that, when operably linked to a polynucleotide encoding a gene product, results in the production of a gene product in the cell under most or all conditions of the cell. A promoter can be a "regulatable" promoter that is a promoter whose activity is affected by a cis or trans acting factor (e.g., an inducible promoter, such as an external signal or agent). The term "inducible" promoter means that when the promoter is operably linked to a polynucleotide encoding a specified gene product, it results in the production of a gene in the cell basically only when the inducer corresponding to the promoter is present in the cell. A promoter can be a "ubiquitous" promoter that is a promoter that is active in a wide range of cells, tissues and cell cycles, or a "tissue-specific" promoter, that is a promoter that has activity only or mostly in certain cell types, i.e., drives the expression of the operably linked nucleotide sequence only or mostly in certain cell types. A promoter can be a "bidirectional" promoter, which is a promoter that is an intergenic region between two divergent genes located on complementary strands of the DNA, and drives their coordinated transcription in opposite directions.
[0038] As used herein, the term "regulatory sequence" refers to a nucleic acid sequence capable of regulating the expression of a nucleic acid sequence operably linked to said regulatory sequence, non-limiting examples of regulatory sequences are enhancers (a DNA sequence that increases the level of transcription of an operably linked gene), and silencers (a DNA sequence94924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 that decreases the level of transcription of an operably linked gene). The term "regulatory sequence" also refers to nucleic acid sequence in RNA transcripts capable of regulating, for example, the processing or the expression of said transcripts. Non-limiting examples of regulatory sequences that can be in RNA transcripts are nucleotide sequences that regulate localization or splicing of said RNA transcripts. The term "regulatory sequence" further refers to an amino acid sequence capable of regulating, for example, the localization (e.g., subcellular localization signals, such as nuclear localization signals), or the stability (e.g., degradation signals) of a protein.
[0039] The terms "operatively linked," "operatively inserted," "operatively positioned," "under control" means, with reference to two or more nucleic acid sequences, that the nucleic acid sequences are arranged in such a way that one of the two or more nucleic acid sequences can mediate a function that is exerted upon at least one of the other two or more nucleic acid sequences. For example, a regulatory nucleic acid sequence e.g., a promoter, an enhancer, or a silencer) can be "operatively linked," to a coding nucleic acid sequence, that is the regulatory nucleic acid sequence is in the correct location and orientation in relation to the coding nucleic acid sequence to control expression of the coding nucleic acid sequence (e.g., via control of RNA polymerase initiation). Wherein a regulatory nucleic acid sequence (e.g., a promoter, an enhancer, or a silencer) is "operatively linked," to a coding region, the coding region is "under transcriptional control" of the regulatory nucleic acid sequence (e.g., a promoter, an enhancer, or a silencer).
[0040] The term "operably linked" means that a nucleic acid sequence and a regulatory sequence(s) are arranged in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s). The term "operably inserted" means that a nucleic acid sequence of interest is positioned adjacent a regulatory nucleic acid sequence which directs transcription and translation of the nucleic acid sequence of interest (i.e., facilitates the production of, e.g., a polypeptide encoded by a DNA of interest).
[0041] As used herein, the term " RNA" relates to a nucleic acid molecule that comprises ribonucleotide residues. In some aspects, the RNA contains all or a majority of ribonucleotide residues. As used herein, "ribonucleotide" refers to a nucleotide with a hydroxyl group at the 2'-position of a b-D-ribofuranosyl group. RNA encompasses without limitation, double stranded RNA, single stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as modified RNA that differs from naturally occurring RNA by the addition, deletion, substitution and / or alteration of one or more nucleotides.104924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01Such alterations may refer to addition of non-nucleotide material to internal RNA nucleotides or to the end(s) of RNA. It is also contemplated herein that nucleotides in RNA may be non-standard nucleotides, such as chemically synthesized nucleotides or deoxynucleotides. For the present disclosure, these altered RNAs are considered analogs of naturally-occurring RNA. The term "mRNA," as used herein, refers to a single stranded RNA that encodes the amino acid sequence of one or more peptide (e.g., oligopeptide, or polypeptide) or protein. The term "mRNA," as used herein includes in vitro transcribed RNA (IVT RNA) or synthetic RNA. An mRNA molecule may also contain a 5' untranslated region (5'-UTR), and / or a 3' untranslated region (3'-UTR). In some aspects, the RNA is produced by in vitro transcription or chemical synthesis. In some aspects, the mRNA is produced by in vitro transcription using a DNA template where DNA refers to a nucleic acid that contains deoxyribonucleotides.
[0042] As used herein the term "splicing" refers to the process by which introns are removed from primary transcripts (pre-mRNA) and exons are joined to form the mature mRNA. Introns are removed by the pre-mRNA by cleavage at conserved sequences called "splice sites", or "splicing sites". These sites are located at the 5' and 3' ends of introns. Most commonly, the RNA sequence that is removed begins with the dinucleotide GU at its 5' end, and ends with AG at its 3' end. These consensus sequences are known to be critical, because changing one of the conserved nucleotides may result in the inhibition of splicing. Another important sequence occurs at what is called the branch point, located anywhere from 18 to 40 nucleotides upstream from the 3' end of an intron. The branch point always contains an adenine, but it is otherwise loosely conserved. A typical sequence is YNYYRAY, where Y indicates a pyrimidine, N denotes any nucleotide, R denotes any purine, and A denotes adenine. Rarely, splice site sequences are found that begin with the dinucleotide AU and end with AC, these are spliced through a similar mechanism.
[0043] Splicing occurs in several steps and is catalyzed by small nuclear ribonucleoproteins (snRNPs, commonly pronounced "snurps"). First, the pre-mRNA is cleaved at the 5' end of the intron following the attachment of a snRNP called U1 to its complementary sequence within the intron. The cut end then attaches to the conserved branch point region downstream through pairing of guanine and adenine nucleotides from the 5' end and the branch point, respectively, to form a looped structure known as a lariat. The bonding of the guanine and adenine bases takes place via a chemical reaction known as transesterification, in which a hydroxyl (OH) group on a carbon atom of the adenine attacks the bond of the guanine nucleotide at the splice site. The guanine residue is thus cleaved from the RNA strand and forms a new bond with the adenine.114924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01
[0044] Next, the snRNPs U2 and U4 / U6 appear to contribute to positioning of the 5' end and the branch point in proximity. With the participation of U5, the 3' end of the intron is brought into proximity, cut, and joined to the 5' end. This step occurs by transesterification; in this case, an OH group at the 3' end of the exon attacks the phosphodiester bond at the 3' splice site. The adjoining exons are covalently bound, and the resulting lariat is released with U2, U5, and U6 bound to it. In addition to consensus sequences at their splice sites, eukaryotic genes with long introns also contain exonic splicing enhancers (ESEs). These sequences, which help position the splicing apparatus, are found in the exons of genes and bind proteins that help recruit splicing machinery to the correct site. Most splicing occurs between exons on a single RNA transcript, but occasionally trans-splicing occurs, in which exons on different pre-mRNAs are ligated together.
[0045] The splicing process occurs in cellular machines called spliceosomes, in which the snRNPs are found along with additional proteins. The primary variety of spliceosome is one of the most plentiful structures in the cell, and recently, a secondary type of spliceosome has been identified that processes a minor category of introns. These introns are referred to as U12-type introns because they depend upon the action of a snRNP called U12 (the common introns described above are called U2-type introns). The role of U12-type introns is not yet defined, but their persistence throughout evolution and conservation between homologous genes of widely divergent species suggests an important functional basis.
[0046] As used herein, the term "alternative splicing" refers to a deviation from the constitutive splicing in which introns are removed and exon are in the order in which they appear in a gene. In alternative splicing certain exons are skipped resulting in various forms of mature mRNA from a single pre-RNA transcript. Weaker splicing signals at alternative splice sites, shorter exon length or higher sequence conservation surrounding orthologous alternative exons influence the exons that are ultimately included in the mature mRNA. Three possible mechanisms: exon shuffling, exonization of transposable elements and constitutively spliced exons, have been proposed for the origin of alternative splicing. Alternative splicing is the mechanism that accounts for the discrepancy between the number of protein-coding genes (-25,000) in humans and the >90,000 different proteins that are actually generated.
[0047] The term "expression" as used herein refers to a process by which a gene produces a biochemical, for example, an RNA transcript or a protein. The process includes any manifestation of the functional presence of the gene within the cell including, without limitation, gene knock-in, as well as both transient expression and stable expression. It may include, without limitation,124924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 transcription of the gene into messenger RNA (mRNA), and the translation of such mRNA into protein(s). Expression of a gene produces a "gene product." As used herein, a gene product can be either a nucleic acid, e.g., a messenger RNA, or a non-coding RNA, produced by transcription of a gene, or a protein, which is translated from an mRNA transcript. Gene products described herein further include nucleic acids with post transcriptional modifications, e.g., mRNAs which are processed, for example, by capping, splicing, and / or polyadenylation, or peptides with post translational modifications, e.g., methylation, glycosylation, the addition of lipids, association with other protein subunits, proteolytic cleavage, and the like. Thus, term "protein expression" refers to the process by which a nucleic acid sequence undergoes transcription (DNA) translation (RNA) such that detectable levels of the amino acid sequence or protein are expressed.
[0048] As used herein, the terms "protein," "polypeptide," and "peptide," are used interchangeably to refer to a natural or synthetic molecule comprising two or more amino acids linked by the carboxyl group of one amino acid to the alpha amino group of another. The amino acids may be natural or synthetic, and can contain chemical modifications such as disulfide bridges, substitution of radioisotopes, phosphorylation, substrate chelation (e.g., chelation of iron or copper atoms), glycosylation, acetylation, formylation, amidation, biotinylation, and a wide range of other modifications. A polypeptide may be attached to other molecules, for instance molecules required for function. Examples of molecules which may be attached to a polypeptide include, without limitation, cofactors, polynucleotides, lipids, metal ions, phosphate, etc. A polypeptide is comprised of approximately twenty, standard naturally occurring amino acids, although natural and synthetic amino acids, which are not members of the standard twenty amino acids, may also be used. The standard twenty amino acids include alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine (Cys, C), glutamine (Gin, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine, (His, H), isoleucine (He, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (Vai, V). These letters as used in terms of a " polypeptide sequence" or "amino acid sequence" are an alphabetical representation of a polypeptide molecule. A polypeptide may be naturally occurring, recombinant, or synthetic, or any combination of these. A polypeptide may also comprise a fragment of a naturally occurring polypeptide. The term polypeptide may also apply to amino acid polymers in which one or more amino acid residues are an artificial chemical analogue of a corresponding naturally occurring amino acid.134924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01
[0049] A polypeptide as disclosed herein can be of a size of about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more, 1,000 or more, or 2,000 or more amino acids. Polypeptides can have a defined three-dimensional structure, although they do not necessarily have such structure. Polypeptides with a defined three-dimensional structure are referred to as folded, and polypeptides that do not possess a defined three-dimensional structure, but rather can adopt a large number of different conformations, and are referred to as unfolded. Non-limiting examples of polypeptide include polypeptide fragments, denatured / unstructured polypeptide, polypeptide having a primary, a polypeptide, a polypeptide, or a polypeptide or aggregated structure, etc. A polypeptide may be a single molecule or may be a multi-molecular complex. There is expressly no requirement that a polypeptide must contain an intended function; a polypeptide can be functional, non-functional, function for unexpected / unintended purposes, or have unknown function.
[0050] As used herein, the term "domain" when referred to a polypeptide means a distinct functional and / or structural portion of a polypeptide. Usually domains are responsible for a particular function or interaction, contributing to the overall role of a polypeptide. Domains may exist in a variety of biological contexts, where similar domains can be found in polypeptide with different functions. For example, an "actin-binding domain" or " ABD" is to be understood as a portion of a polypeptide that is involved in the binding of the polypeptide with actin. For example, an ABD can comprise one or more amino acids that directly bind to actin.
[0051] As used herein, the term "truncated" when referred to a protein means a protein that is lacking one or more portion with the respect to the full length protein. A protein can lack, for example, an amino-terminal portion, a carboxy-terminal portion, any portion in between the two termini, or any combination thereof.
[0052] By "isolated" molecule (e.g, a protein or a nucleic acid molecule) is intended a molecule, which has been removed from its native environment. An isolated molecule includes molecules produced and maintained (e.g, upon purification) in vitro, or recombinant molecules maintained in host cells or purified (partially or substantially) from the host cell and maintained in solution. Non-limiting examples of isolated molecules include proteins or nucleic acid molecules extracted from a cell, produced synthetically (i.e., by chemical synthesis), produced by enzymatic digestion; DNA molecules produced by PCR, produced by in vitro retro-transcription (cDNA), by molecular cloning in a vector (e.g., a viral or a non-viral vector); RNA transcripts produced by in vitro transcription or produced in host cells (e.g., a heterologous host cells) and maintained in the144924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 host cell or purified (partially or substantially) from the host cell and maintained outside of the cell; proteins produced by in vitro translation or produced in host cells (e.g., a heterologous host cells) and maintained in the host cell or purified (partially or substantially) from the host cell and maintained outside of the cell.
[0053] As used herein, "purify," "purified," "purification" means to make substantially pure or clear from unwanted components, material defilement, admixture or imperfection.
[0054] As used herein, the term "variant" refers to an alternative molecule (e.g., an alternative genomic sequence, transcript, or protein) that differs from the corresponding wild type molecule. As used herein, the term "wild type," refers to a strain, a molecule (e.g., a nucleic acid (e.g., a gene or a transcript) or a protein) or characteristic, which prevails among individuals in natural conditions, and it is distinct from a variant of the strain, molecule (e.g., nucleic acid (e.g., gene or transcript) or protein), or characteristic. A variant may differ from the wild type molecule in any region of the molecule, for example, in any domain of a protein, in any regulatory region of a protein or nucleic acid molecule, or in any coding or non-coding region of a nucleic acid molecule, or any combination thereof. A variant may be present in any percentage of the population (e.g., <0,001%, or >10%). A variant may or may not cause phenotypic changes, and may or may not cause a disorder, disease, syndrome, or condition. A variant can be present in all the cells of an individual, or in some of the cells of the individual (e.g., in some cell lineages of the individual).
[0055] A variant genomic sequence or transcript can comprise one or more nucleotide differences with respect to the wild type sequence, such as indels (i.e., insertions and / or deletion), nucleotide expansions, transversions, translocations, inversions, chromosomal structure alterations, gene fusions, chromosome fusions, truncations, amplifications, duplications, chromosomal lesions, or any combination thereof. As a result, a variant nucleotide sequence can be altered at a single nucleotide, which may be added, deleted, or substituted, or at more than one nucleotide. Further the structure of a chromosome can be altered, with regions being flipped, deleted, duplicated, truncated, or translocated. The expression of a gene can also be amplified (or reduced) through increased (or decreased) copy number of a gene; this scenario is defined as "copy number variation. "
[0056] A variant genomic sequence can arise, for example, from unrepaired DNA damage, replication errors, or mobile genetic elements. A variant genomic sequence can be inherited from parents (i.e., may be present in the germline of one or both parents) or can be acquired over the life of an individual i.e., appear at any time over the life of an individual in the somatic or germ line154924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 of the individual). It is also to be understood that "a copy of a gene that is not a wild type copy of the gene," is herein intended to refer to a variant of the gene. It is understood, that a gene (e.g., the DMD gene) is to be intended as the whole genomic region, i.e., comprising coding regions, noncoding regions, regulatory regions, or any combination thereof.
[0057] It is to be understood that the term a "variant" further encompasses proteins encoded by variant genomic sequences or transcripts.
[0058] A variant transcript can also be encoded and / or produced from the same genomic region from which the wild type molecule is encoded and / or produced, but yet differ from the wild type molecule encoded and / or produced from the same genomic region as a results of differences introduced during the transcription process and / or during RNA processing (e.g., may be the product of alternative splicing).
[0059] Additionally, a variant protein can be encoded or produced from the same genomic region or transcript as the wild type protein, but yet differ from the wild type protein as a results of differences introduced during the translation process.
[0060] As used herein, the term "recombinant DNA / RNA technology" refers to the manipulation of nucleic acid sequences outside of an organism. This technology comprises, but is not limited to, combining nucleic acid sequences (e.g., coding sequences, regulatory elements (e.g., promoters, enhancers, silencers, termination sequences), linkers (e.g., spacers, internal ribosome entry sites, cleavage sites)) derived from a variety of sources, inserting nucleic acid sequences from a variety of sources in appropriate vectors e.g., delivery vectors, expression vectors, integrating vectors), modifying or altering nucleotide sequences (e.g., by mutagenesis, insertion of modified nucleotides, 5'-capping, polyadenylation), synthesizing artificial nucleotide sequence. A variety of techniques described in the literature (e.g., molecular cloning, polymerase chain reaction (PCR), digestion with restriction enzymes, in vitro ligation, mutagenesis, site-directed mutagenesis, prokaryotic and eukaryotic cell transformation or transduction, in vitro DNA / RNA synthesis, in vitro RNA-5'-capping, in vitro RNA-polyadenylation, complementary DNA (cDNA) synthesis, nucleic acid isolation, and the like) can be used to manipulate nucleic acid sequences outside an organism (see for example Green & Sambrook Molecular Cloning: A Laboratory Manual, volumes 1-3, 4thedition).
[0061] As used herein, the term "recombinant" or "engineered" refers to any nucleic acid (e.g., DNA, or RNA), peptide (e.g., oligopeptide, polypeptide, protein, or protein domain), cell, or organism, which is made by manipulation of nucleic acid or amino acid sequences. For example,164924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01"engineered DNA" molecules are DNA molecules that are manipulated outside of (e.g., via recombinant DNA / RNA technology) or inside an organism (e.g., via transgenesis), to obtain a non-naturally occurring DNA molecule. An "engineered DNA" molecule can comprise, for example, one or more nucleotide variations compared to the DNA molecule from which it is derived. The "engineered DNA" molecule can be transcribed into RNA, which is referred to as an "engineered RNA" molecule. The "engineered RNA" molecule can be translated into a polypeptide or a polypeptide domain, which is referred to as an "engineered polypeptide" or an "engineered polypeptide domain." Thus, an "engineered polypeptide" or an "engineered polypeptide domain" can be any polypeptide or polypeptide domain, which is encoded by nucleic acids manipulated via recombinant DNA / RNA technology, additionally, an "engineered polypeptide" or an "engineered polypeptide domain" can be produce by chemical synthesis. An "engineered polypeptide" or an "engineered polypeptide domain" can be for example a truncated polypeptide or polypeptide domain, or a polypeptide or polypeptide domain comprising one or more amino acid substitutions compared to a same polypeptide or polypeptide domain that is not engineered.
[0062] An engineered polypeptide or polypeptide domain can be manipulated without the purpose of achieving a desired altered function of the polypeptide or polypeptide domain, or with the purpose of achieving a desired altered function of the polypeptide or polypeptide domain. For example, an engineered polypeptide or polypeptide domain can be modified to increase a function or characteristic of the polypeptide or polypeptide domain (e.g., to increase the binding affinity of the engineered polypeptide or polypeptide domain for a specific target (e.g., a second polypeptide or polypeptide domain)). These modifications are referred to as gain-of-function / characteristic modifications and result in gain-of-function / characteristic polypeptides or polypeptide domains. For example, a polypeptide or polypeptide domain can be modified to achieve increased binding affinity to a specific target (e.g., a second polypeptide or polypeptide domain) (i.e., the function / characteristic of the polypeptide or polypeptide domain that is increased by the modification is the binding affinity to a specific target of the polypeptide or polypeptide domain), these modified polypeptides or polypeptide domains are referred to as gain-of-affinity or GoA-polypeptides or GoA-polypeptide domains. Alternatively, a polypeptide or polypeptide domain can be modified to decrease a function or characteristic of the polypeptide or polypeptide domain. These modifications are referred to as loss-of-function / characteristic modification, resulting in loss-of-function / characteristic polypeptide or polypeptide domains).174924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01
[0063] As used herein the term "amino acid substitution" refers to the replacement of one amino acid in a protein with a different amino acid. An "amino acid substitution" can be naturally occurring or experimentally induced. For example, an "amino acid substitution" can be introduced in a protein via manipulation of the nucleic acid molecule encoding for the protein by "recombinant DNA / RNA technology." Typically, amino acid substitution are indicated as XNY, wherein X indicates the amino acid present at position N before the amino acid substitution, and Y indicates the amino acid present at position N after the amino acid substitution. Thus, for example T20A indicates that a T was present at potion 20 before the amino acid substitution, and an A is present at the same position 20 after the amino acid substitution.
[0064] As used herein, the term "genetic locus, " refers to the physical site or location within a genome of a specific DNA sequence, for example a gene.
[0065] As used herein, the term "transgene" refers to a gene (e.g., micro-dystrophin gene) or a nucleic acid molecule that is introduced into a cell. An example of a transgene is a nucleic acid encoding a therapeutic protein. In some aspects, the gene can be present, but in some cases, the gene is not expressed or is expressed at an insufficient level in the cell. In this context, "insufficient" means that although said gene is expressed in the cell, a condition and / or disease could still be developed. In certain aspects, the transgene allows for the increased expression or over-expression of the gene. The transgene can comprise sequences that are native to the cell, sequences that do not naturally occur in the cell, or combinations of both. In certain aspects, the transgene can comprise a sequence that can be operably linked to appropriate regulatory sequences for expression of the gene in the cell. In some aspects, the transgene is integrated into the host cell's genome. In some aspects, the transgene is not integrated into the host cell's genome.
[0066] The term "vector" as used herein includes any vectors known to the skilled person including plasmid vectors, cosmid vectors, phage vectors such as lambda phage, viral vectors such as retroviral, adenoviral or baculoviral vectors, or artificial chromosome vectors such as bacterial artificial chromosomes (BAC), yeast artificial chromosomes (YAC), or Pl artificial chromosomes (PAC). Said vectors include expression as well as cloning vectors. Expression vectors comprise plasmids as well as viral vectors and generally contain a desired coding sequence and appropriate DNA sequences necessary for the expression of the operably linked coding sequence in a particular host organism (e.g., bacteria, yeast, plant, insect, or mammal) or in in vitro expression systems. Cloning vectors are generally used to engineer and amplify a certain desired DNA fragment and may comprise specific functional sequences needed for insertion and / or expression of the desired184924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01DNA fragments. A "vector" can be any vehicle for the cloning of and / or transfer of a nucleic acid into a host cell, such as a plasmid, phage, transposon, cosmid, chromosome, artificial chromosome, virus, virion, etc. The term "vector" includes both viral and nonviral vehicles for introducing the nucleic acid into a cell in vitro, ex vivo or in vivo. In some aspects, insertion of a polynucleotide into a suitable vector can be accomplished by ligating the appropriate polynucleotide fragments into a chosen vector that may or not have complementary cohesive termini. Vectors can be engineered to encode selectable markers or reporters that provide for the selection or identification of cells that have incorporated the vector. Expression of selectable markers or reporters allows identification and / or selection of host cells that incorporate and express other coding regions contained on the vector. Examples of selectable marker genes described in the literature include: genes providing resistance to neomycin, ampicillin, streptomycin, gentamycin, kanamycin, hygromycin, bialaphos herbicide, sulfonamide, and the like; and genes that are used as phenotypic markers, i.e., anthocyanin regulatory genes, isopentanyl transferase gene, and the like. Examples of reporters described in the literature include: luciferase (Luc), green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), P-galactosidase (LacZ), P-glucuronidase (Gus), and the like. Selectable markers can also be considered to be reporters.
[0067] As used herein, the term "adeno-associated vector" or " AAV vector" refers to a vector comprising one or more polynucleotides of interest (e.g., transgenes, such as microdystrophin) that are flanked by AAV terminal repeat sequences (ITRs). AAV is a single-stranded DNA parvovirus that grows only in cells in which certain functions are provided by a co-infecting helper virus. General information and reviews of AAV can be found in, for example, Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169-228, and Berns, 1990, Virology, pp. 1743-1764, Raven Press, (New York); Blacklowe, 1988, pp. 165-174 of Parvoviruses and Human Disease, J. R. Pattison, ed.; and Rose, Comprehensive Virology 3:1-61 (1974)). Such AAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that has been transfected with a vector encoding and expressing rep and cap gene products. " AAV Cap" means AAV Cap proteins, VP1, VP2, and VP3 and analogs thereof. " AAV Rep" means AAV Rep proteins and analogs thereof. " Serotype," with respect to a vector or virus capsid, is defined by a distinct immunological profile based on the capsid protein sequences and capsid structure. Non-limiting examples of AAV serotypes are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV6.2, AAV6P1, AAV7, AAV8, AAV8P1, AAV9, AAVrhlO, AAVrhlOPl, AAVrh74, AAVS10P4, AAVpol, AAV11, AAV12, AAV-DJ, AAV-DJ / 8, AAV-PHP. Eb, AAV-PHP. S, AAV-PHP. B,194924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01AAV2-retro, AAV2-QuadYF, AAV2.7m8, AAVS1, AAVS10, AAVrh74, AAVS1, AAVS10, AAVH15, AAVMYO (AAV9P1), AAVMYO 2 (AAVS1P1), AAVMYO3 (AAVS10P1), AAV9-RGD (e.g., MyoAAVlA, MyoAAV 1C, MyoAAV IE, MyoAAV 2A, MyoAAV 2E, MyoAAV 3 A, MyoAAV 4A, MyoAAV 4C, MyoAAV 4E, and variants thereof.
[0068] As used herein, "flanked," with respect to a sequence that is flanked by other elements, indicates the presence of one or more the elements upstream and / or downstream, z.e., 5' and / or 3', relative to the sequence. The term "flanked" is not intended to indicate that the sequences are necessarily contiguous. For example, there may be intervening sequences between the nucleic acid encoding the transgene and a flanking element. A sequence (e.g., a transgene) that is "flanked" by two other elements (e.g., ITRs), indicates that one element is located 5' to the sequence and the other is located 3' to the sequence; however, there may be intervening sequences between.
[0069] As used herein, the terms " AAV virion," " AAV viral particle," or " AAV particle" refer to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. The particle can comprises a heterologous polynucleotide (z.e., a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell). An AAV particle comprising a heterologous polynucleotide can be also referred to as a "recombinant AAV particle," "recombinant AAV vector," "rAAV particle," or "rAAV vector."
[0070] As used herein, the term "transfection" of a cell refers to the introduction of genetic material into a cell by means of a non-viral vector for the purpose of genetically modifying the cell.
[0071] As used herein, the term "transduction" of a cell refers to the introduction of genetic material into a cell by means of a viral vector for the purpose of genetically modifying the cell. For example, the coding region of a gene or of a portion thereof (e.g., a micro-dystrophin) can be administrated / delivered to a recipient cell either in vivo or in vitro, via an AAV particle resulting in the expression of the gene or portion thereof (e.g., a micro-dystrophin) in the recipient cell.
[0072] As used herein, the term "cell" or "cells" refers not only to the particular subject cell, but also to the progeny or to the potential progeny of such cell(s). The scope of the term as used herein also encompasses the progeny that may or may not in fact be identical to the parent cell because certain modifications may occur in succeeding generations due to either mutation or environmental influences. A cell can be, for example, a "muscle cell," which is a cell derived from a muscle of any kind (for example, skeletal muscle and smooth muscle, e.g. from the digestive204924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 tract, urinary bladder, blood vessels or cardiac tissue), as well as a cell differentiated in vitro to possess the characteristics of a cell derived from a muscle of any kind. Such muscle cells may be differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes, and cardiomyoblasts. A cell group of muscle cells can for a "muscle tissue."
[0073] The term "muscle specific control element" refers to a nucleotide sequence that regulates expression of a coding sequence that is specific for expression in muscle tissue. These control elements include enhancers and promoters. Exemplary muscle specific control elements include, but are not limited to, the MCKH7 promoter, the MCK promoter and the MCK enhancer.
[0074] As used herein, the terms “neurotrophin-3,” “NTF3,” and “NT-3” each refer to the protein product of the NTF3 gene (NCBI Gene ID: 4908; NCBI Protein Accession No.: NP_001096124.1; UniProt: P20783. Neurotrophin-3 belong to the NGF-beta family of neurotrophic factors and is expressed in the brain and peripheral tissues. NT-3 has been shown to promote survival of peripheral neurons through preservation of Schwann cells and myelination.
[0075] As used herein, the terms "pharmaceutical formulation" or "pharmaceutical composition" refer to an admixture comprising an effective amount of a therapeutically and / or prophylactic effective agent and at least one pharmaceutically acceptable excipient (e.g., carrier, diluent, stabilizer, or any combination thereof) or adjuvant. Examples of pharmaceutically acceptable excipients are, but are not limited to, carriers, binders, diluents, lubricants, thickeners, surface active agents, preservatives, stabilizers, emulsifiers, buffers, flavoring agents, colorants, amino acids, stabilizers, bulking agents, surfactants, antimicrobials, preservatives, metal ions, chelators, cyclodextrin-based excipients, polyanions, polycations, salts, solubilizers, detergents, compatible solid or liquid fillers, encapsulating substances, or any combination thereof, which are suitable for administration to a subject. Specific examples of excipient include, without limitation, sterile water, Ringer, Ringer lactate, sterile sodium chloride solution, isotonic saline, polyalkylene glycols, hydrogenated naphthalenes and, biocompatible lactide polymers, lactide / glycolide copolymers or polyoxyethylene / polyoxy-propylene copolymers, or any combination thereof. Examples of pharmaceutically acceptable carriers are, but are not limited to, lipids, polymers, polysaccharides, peptides, proteins, lipidoids, and any combination thereof. In some aspects, the lipid is selected from the group consisting of: cationic lipids, non-cationic lipids, steroid lipids, ionizable lipids, PEG-conjugated lipids, and any combination thereof. In some aspects, the fusion proteins, the expression cassettes, and the vectors disclosed herein are complexed, or packaged in a liposome, a nanoliposome, a lipid nanoparticle, a lipoplex, a micelle, a nanomicelle, a214924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 nanoemulsion, an oil-in-water emulsions, a PEG-conjugated lipid nanoparticle, a polymeric nanoparticle, a lipid-polymer hybrid nanoparticle, a polysaccharidic nanocarrier, an RNA / DNA-peptide nanoparticle, an RNA / DNA -peptide nanocomplex, a biomimetic nanovesicle, a lipidoid-RNA / DNA complex, a virus-like particle, dendrimer nanoparticle, a nanogel, a metallic nanoparticle, a gold nanoparticle (AuPNs), a magnetic nanoparticle, a theranostic nanoparticle, or any combination thereof. In some aspects, the combination of the fusion proteins, the expression cassettes, and the vectors disclosed herein with one or more of the carriers described herein facilitates, enhances or enables administration of the fusion proteins, the expression cassettes, and the vectors disclosed herein to the subject. In some aspects, the combination of a therapeutic agent with one or more of the carriers described herein facilitates, enhances or enables the delivery of the therapeutic agent to a target cell.
[0076] Pharmaceutically acceptable excipients for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R Gennaro edit. 1985). Pharmaceutical excipients can be selected with regard to the intended route of administration and standard pharmaceutical practice.
[0077] As used herein, a "therapeutic agent" refers to a chemical compound, a peptide, a protein, a lipid, a carbohydrate, a nucleic acid, or any other molecule or compound capable of treating, ameliorating, or reducing the symptoms of a disease, a disorder, a condition, or a syndrome, or otherwise having a beneficial effect, upon administration to a subject suffering from the disease, disorder, condition, or syndrome.
[0078] As used herein, the term "administration" refers to the administration of a composition or substance to a subject or system. Administration to an animal subject (e.g., to a mammal) can be by any appropriate route. " Administering" refers to the physical introduction of a composition or substance, which may comprising a therapeutic agent, to a subject, using any of the various methods and delivery systems known to those skilled in the art. Examples of routes of administration include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion. The phrase "parenteral administration" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, as well as in vivo224924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 electroporation. Administration can also be via a non-parenteral route, for example, orally. Other non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, aborally, sublingually or topically. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.
[0079] As used herein, the terms "treat," "treated," and "treating" mean both therapeutic and prophylactic treatment or preventative measures wherein the object is to reverse, alleviate, ameliorate, lessen, inhibit, slow down progression, development, severity or recurrence of an undesired symptom, complication, condition, biochemical indicia of a disorder, or disease, or obtain beneficial or desired clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of a condition, disorder, or disease; stabilized (i.e., not worsening) state of condition, disorder, or disease; delay in onset or slowing of condition, disorder, or disease progression; amelioration of the condition, disorder, or disease state or remission (whether partial or total), whether detectable or undetectable; an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient; or enhancement or improvement of condition, disorder, or disease. In some aspects, treatment includes eliciting a clinically significant response without excessive levels of side effects. In some aspects, treatment includes prolonging survival as compared to expected survival if not receiving treatment. As used herein, the term "amelioration" or "ameliorating" refers to a lessening of severity of at least one indicator of a condition or disease. As used herein, the term "preventing" or "prevention" refers to delaying or forestalling the onset, development or progression of a condition or disease for a period of time, including weeks, months, or years. As used herein, the term "prophylactic" (e.g., "prophylactic agent", "prophylactic treatment", "prophylactically effective amount"), refers to any complete or partial prevention of a disease or symptom thereof and / or can be therapeutic in terms of a partial or complete cure for a disease and / or adverse effect and / or symptom attributable to the disease.
[0080] As used herein, the term "gene therapy" refers to the administration into an individual's cells and / or tissues of an exogenous molecule (e.g., a nucleic acid sequence (e.g., a polynucleotide comprising a promoter operably linked to a nucleic acid encoding a gene product capable of interfering with the genomic sequence of the individual's cells and / or tissues)) to treat, reduce the symptoms of, or reduce the likelihood of a disease, disorder, syndrome, or condition. An exogenous molecule or sequence is understood to be molecule or sequence not normally234924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 occurring in the cell, tissue and / or individual to be treated. Both acquired and congenital diseases are amenable to gene therapy.
[0081] As used herein, the term "subject" refers to any organism to which a composition or a substance (e.g., a nucleotide molecule) can be administered, e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include any animal. A subject can seek or be in need of treatment, require treatment, be receiving treatment, be receiving treatment in the future, or be under care by a trained professional for a particular disease or condition.
[0082] As used herein, the term "expression cassette" refers to a nucleic acid molecule, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleotide sequence in a competent host cell, such that a particular gene product (e.g., RNA or protein) is expressed. Expression of any gene product may be dependent upon presence of cellular factors or additional gene products from other expression cassettes. An expression cassette may be part of a vector, such as a plasmid, a viral genome, or a nucleic acid fragment. Typically, an expression cassette includes a polynucleotide to be transcribed, operably linked to a promoter.
[0083] As used herein, the terms "genetic construct" or "construct" refer to a nucleic acid molecule (RNA, DNA, or a combination thereof) made recombinantly or synthetically comprising one or more nucleotide sequences, such as a nucleotide sequence encoding (i.e., a coding sequence) a particular gene product (e.g., RNA or protein), and comprising initiation and termination signals; a regulatory element, such as a promoter; and / or a polyadenylation signal. The one or more nucleotide sequences comprised in a genetic construct can be operably linked, such that they are capable of directing expression of the coding sequence in a cell, such as a cell maintained in culture (in vitro), or a cell comprised in an individual in vivo), to which the genetic construct is administered. A genetic construct can be, for example, an expression cassette, or a vector, e.g., a vector comprising an expression cassette.
[0084] As used herein, the terms “percent identity” and / or “percent identical,” as applicable to a particular nucleotide or amino acid sequence, refer to the proportion of identical residues between this particular reference sequence and another sequence, as calculated by a pairwise alignment using the Needleman-Wunsch algorithm using a generally available alignment program, e.g., the Needle (EMBOSS) program.
[0085] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure244924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 5th ed., 2013, Academic Press; and the Oxford Dictionary of Biochemistry and Molecular Biology, 2006, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.
[0086] Units, prefixes, and symbols are denoted in their Systeme International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.
[0087] Various aspects of the invention are described in further detail in the following subsections.Payload Polynucleotides encoding NT-3 Proteins
[0088] In some aspects, disclosed herein are payload polynucleotides comprising, or alternatively consisting essentially of, or yet further consisting of a nucleotide sequence encoding a neurotrophin-3 (NT-3) polypeptide. In some aspects, the polynucleotides consist of about 0.5 kb, 1 kb, 1.5 kb, 2 kb, 2.5 kb, 3 kb, 3.5 kb, 4 kb, 4.5 kb, 5 kb, 5.5 kb, 6 kb. In some aspects, the payload polynucleotides have a size that is suitable for cloning in a vector. In some aspects, the payload polynucleotides have a size that is suitable for cloning in a viral vector. In some aspects, the payload polynucleotides have a size that is suitable for cloning in an AAV vector.
[0089] In some aspects, the payload polynucleotides disclosed herein further comprise additional nucleotide sequences. In some aspects, the payload polynucleotides disclosed herein can be expression cassettes encoding a neurotrophin-3 (NT-3) polypeptide.
[0090] In some aspects, the payload polynucleotides disclosed herein further comprise a promoter, a Kozak sequence, an enhancer, a silencer, a poly A tail, a polyadenylation signal, a 3'-UTR, a 5'-UTR, an intronic sequence, a nucleotide sequence encoding a molecular tag, a nucleotide sequence encoding a selectable marker, a nucleotide sequence encoding a self-cleaving peptide, a linker, a filler sequence, any combination thereof, or any other nucleotide sequence that may facilitate the expression of the nucleotide sequences encoding the polypeptides disclosed herein. Any further nucleotide sequences present in the polynucleotide are in the appropriate position254924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 required to exert its function. For example, the nucleotide sequence of a promoter is operably linked to the nucleotide sequence encoding the polypeptides disclosed herein.
[0091] In some aspects, the payload polynucleotide of the disclosure comprises:(i) a MCK promoter; (ii) an intron; (iii) a nucleotide sequence encoding a human NT-3 polypeptide; (iv) an SV40 polyadenylation signal. In further aspects, the payload polynucleotide of the disclosure comprises a first ITR at the 5’ of the polynucleotide and a second ITR at the 3’ of the polynucleotide.Promoters
[0092] The promoter for the payload polynucleotides can be a constitutive, a regulatable, an inducible, an ubiquitous, or a tissue-specific promoter.
[0093] In some aspects, the promoter is a constitutive promoter. Non-limiting example of constitutive promoters are a CBA promoter, a CMV promoter, an EFla promoter, or a CAG promoter.
[0094] In some aspects, the promoter is a tissue-specific promoter. In some aspects, the promoter drives expression of the therapeutic protein, e.g., a neurotrophin-3 protein, in the brain, peripheral nervous system, muscle, kidney, lung, testis, or any combination thereof. In some aspects, the tissue-specific promoter is a muscle tissue-specific promoter. Non-limiting example of tissue-specific promoters are a MHC promoter, a a-MHC promoter, a MLC-2 promoter, a cTnC promoter, a MHCK7 promoter, MHCK promoter, a Enh358MCK promoter, a CK promoter (e.g., hCK or hCK Plus, a CK8e promoter, a MCK promoter, a dMCK promoter, a tMCK promoter (SEQ ID NO: 2), a DES promoter, a HSA promoter, a SPc5-12 promoter, a SP-301 promoter, a MHC promoter, a Sk-CRM promoter, a Sk-CRM4 promoter, or C5-12 promoter. In some aspects, the tissue-specific promoter comprises, or alternatively consists essentially of, or yet further consists of a tMCK promoter. In some aspects, the tissue-specific promoter comprises, or alternatively consists essentially of, or yet further consists of a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2. In some aspects, the promoter comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 2.264924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01Enhancer
[0095] In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of a human skeletal actin gene element, a cardiac actin gene element, a myocyte-specific enhancer binding factor MEF (e.g., MEF2), a MyoD enhancer element, a cardiac enhancer factor (CEF) site, murine creatine kinase enhancer element, skeletal fast-twitch troponin C gene element, slow-twitch cardiac troponin C gene element, the slow-twitch troponin I gene element, hypoxia-inducible nuclear factors, steroid-inducible element, glucocorticoid response element (GRE) or any combination thereof. In some aspects, the enhancer is a MEF2 enhancer. In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of a MyoD enhancer. In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of a MCK enhancer. In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of a CEF site. In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of a SV40 enhancer. In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of a c-Myc enhancer.Intron
[0096] In some aspects, the intron comprises, or alternatively consists essentially of, or yet further consists of a CAG intron, an SV40 intron, MVM intron, or a human beta-globin intron, or any combination thereof. In some aspects, the intron comprises, or alternatively consists essentially of, or yet further consists of a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 3. In some aspects, the intron for the payload polynucleotide comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 3.Poly A
[0097] In some aspects, the poly (A) sequence comprises, or alternatively consists essentially of, or yet further consists of an actin poly(A), a bGHpA, a hGHpA, a SV40pA, or a synthetic pA. In some aspects, the poly(A) sequence comprises, or alternatively consists essentially of, or yet further consists of a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID274924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01NO: 6. In some aspects, the poly(A) tail comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 6.Inverted Terminal Repeats (ITRs)
[0098] In some aspects, the payload polynucleotides further comprise a nucleotide sequence encoding a first inverted terminal repeat (ITR) and a second ITR. In some aspects, the first inverted terminal repeat (ITR) and the second ITR are derived from the same serotype. In some aspects, the first inverted terminal repeat (ITR) and the second ITR are derived from different serotypes. In some aspects, the serotype is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAVrhlO, AAVrh74, AAV11, or AAV12 serotype. In some aspects, the serotype is AAV2 serotype.
[0099] In some aspects, the first ITR sequence comprises, or alternatively consists essentially of, or yet further consists of a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 1. In some aspects, the first ITR sequence comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 1.
[0100] In some aspects, the second ITR sequence comprises, or alternatively consists essentially of, or yet further consists of a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 7. In some aspects, the second ITR sequence comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 7.Exemplary Payload Polynucleotides
[0101] In some aspects, the polynucleotides disclosed herein are isolated polynucleotides. In some aspects, the payload polynucleotide comprises:(i) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(ii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iii) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5; and(iv) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6.
[0102] In some aspects, the payload polynucleotide comprises:284924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01(i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1;(ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5;(v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and(vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7.
[0103] In some aspects, the payload polynucleotide comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 8.
[0104] In some aspects, the polynucleotides disclosed herein are comprised in an expression cassette. In some aspects, the expression cassette is in a vector. Therefore, in some aspects, provided herein is an expression cassette comprising a payload polynucleotide which comprises:(i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1;(ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5;(v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and(vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7.
[0105] In some aspects, the expression cassette comprises, or alternatively consists essentially of, or yet further consists of a payload polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 8.
[0106] In some aspects, provided herein is a vector comprising a payload polynucleotide which comprises:(i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1;(ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5;294924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01(v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and(vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7.
[0107] In some aspects, the vector comprises, or alternatively consists essentially of, or yet further consists of a payload polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 8.
[0108] Vectors comprising the polynucleotides (e.g., expression cassettes) disclosed herein are also provided for herein. In some aspects, the vectors are non-viral vectors. In some aspects, the vectors are viral vectors ( / .<., viral genomes). In some aspects, the viral vectors are AAV vectors, ( / .<., AAV viral genomes).Viral Particles
[0109] Also provided herein is a viral particle comprising the payload polynucleotide disclosed herein, the expression cassette disclosed herein, or the vector disclosed herein. Viral particles comprising the vectors ( / .<., viral genomes, such as AAV viral genomes) disclosed herein are also provided for herein.
[0110] In some aspects, the viral particles disclosed herein are recombinant adeno-associated virus (rAAV) particles. In some aspects, the rAAV particles disclosed herein further comprise a capsid protein.
[0111] In some aspects, provided herein is a recombinant viral (AAV) particle comprising a capsid protein and a payload polynucleotide which comprises:(i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1;(ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5;(v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and(vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7, andwherein the capsid protein is derived from an AAVrh74 capsid protein.
[0112] In some aspects, the rAAV particle comprises, or alternatively consists essentially of, or yet further consists of a capsid protein and a payload polynucleotide comprising the304924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 nucleotide sequence set forth in SEQ ID NO: 8, wherein the capsid protein is derived from an AAVrh74 capsid protein.Capsid Protein
[0113] In some aspects, the capsid protein is derived from AAVrh74 capsid protein. In some aspects, the capsid protein comprises, or alternatively consists essentially of, or yet further consists of an amino acid sequence having at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO: 9. In some aspects, the capsid protein comprises, or alternatively consists essentially of, or yet further consists of the amino acid sequence set forth in SEQ ID NO: 9.
[0114] In some aspects, provided herein is a recombinant viral (e.g., AAV) particle comprising a capsid protein and a payload polynucleotide which comprises:(i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1;(ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5;(v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and(vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7, andwherein the capsid protein comprises, or alternatively consists essentially of, or yet further consists of the amino acid sequence set forth in SEQ ID NO:9.
[0115] In some aspects, the rAAV particle comprises, or alternatively consists essentially of, or yet further consists of a capsid protein and a payload polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 8, wherein the capsid protein comprises, or alternatively consists essentially of, or yet further consists of the amino acid sequence set forth in SEQ ID NO: 9.
[0116] The nucleic acid molecules and the vectors (e.g., AAV vectors) of the disclosure may be produced by any of the suitable means disclosed in the published literature. For example, the nucleic acid molecules may be produced by chemical synthesis or by recombinant DNA314924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 technology. Methods for producing recombinant AAV vectors are disclosed in the published literature (e.g., Kimura, T., Ferran, B., Tsukahara, Y. et al. Production of adeno-associated virus vectors for in vitro and in vivo applications. Sci Rep 9, 13601 (2019); Viral Vectors for Gene Therapy: Methods and Protocols, Manfredsson F. P, Benskey M. J., Springer Link (2019)).
[0117] The genetic code is well known in the published literature, and a person skilled in the art would be readily able to produce a nucleotide sequence encoding a defined amino acid sequence. Thus, a person skilled in the art, provided the amino acids sequence of, e.g., SEQ ID NO: 9, would be readily able to produce a nucleotide sequence encoding the same.
[0118] A person skilled in the art would know the that the four nucleotide bases of DNA: adenine (A), cytosine (C), guanine (G) and thymine (T) — can be used in various ways to spell out three-letter "codons" that specify which amino acid is needed at each position within a protein, and provided any amino acid sequence would be readily able to produce a nucleotide sequence encoding the same. A person skilled in the art would also know that a nucleotide sequence may vary due to the degeneracy of the genetic code. An exemplary representation of the genetic code
[0119] Nevertheless, exemplary nucleotide sequences encoding a neurotrophin-3 (NT-3) of the disclosure are provided in the Sequence Table provided in the present disclosure. In some aspects, the NT-3 polypeptide is encoded by a nucleic acid sequence having at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the nucleic acid sequence set forth in SEQ ID NO: 5.324924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01Pharmaceutical Formulations
[0120] In some aspects, provided herein are pharmaceutical formulations comprising, or alternatively consisting essentially of, or yet further consisting of the nucleic acid molecules, or the vectors disclosed herein, and a pharmaceutically acceptable excipient, or pharmaceutically acceptable adjuvants, or any combination thereof.
[0121] In some aspects, the combination of the nucleic acid molecules or the vectors disclosed herein with one or more of the carriers described herein facilitates, enhances or enables administration of the nucleic acid molecules or the vectors disclosed herein to the subject. In some aspects, the combination of the nucleic acid molecules or the vectors disclosed herein with one or more of the carriers described herein facilitates, enhances or enables the delivery of the nucleic acid molecules or the vectors disclosed herein to a target cell. In some aspects, after administration to the subject of the nucleic acid molecules or the vectors disclosed herein, at least a portion of the nucleic acid molecules or the vectors disclosed herein are delivered to a target cell.Methods of use
[0122] In some aspects, disclosed herein are methods of increasing the amount of neurotrophin-3 (NT-3) protein in a cell comprising, or alternatively consisting essentially of, or yet further consisting of contacting the cell with the nucleic acid molecules, the vectors, or the pharmaceutical formulations disclosed herein.
[0123] In some aspects, the cell is a muscle cell. In some aspects, the muscle cell is derived from skeletal muscle or smooth muscle, e.g. from the digestive tract, urinary bladder, blood vessels or cardiac tissue. In some aspects, the muscle cell is a myoblast, a myocyte, a myotube, a cardiomyocyte, or a cardiomyoblast. In some aspects, the cell is a mammalian cell. In some aspects, the cell is comprised in a subject. In some aspects, the subject suffers from one or more diseases, disorders, syndromes or conditions that can benefit from an increase in NT-3 protein expression and / or activity. In some aspects, the amount of NT-3 protein in the cell is increased of at least 0.1 -fold, 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold compared to a same cell not administered the nucleic acid molecules, the vectors, or the pharmaceutical formulations disclosed herein.334924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01EXAMPLESExample 1: Production of AA Vrh 74 vectors for AA V NT-3 gene therapy
[0124] The scAAVrh74.tMCK. NT-3 plasmid (SEQ ID NO: 12) is a self-complementary plasmid construct with the tMCK promoter and the full human NT-3 cDNA (GenBank designation NTF3) coding sequence. Previous reports have shown NT-3 gene therapy using different capsid serotypes, particularly AAV1 (see, US Patent Application NO. 2024 / 0383956, which is incorporated by reference for all purposes). However, scaling up the AAV1 vector resulted in an inability to produce AAV particles at sufficient scale for gene therapy. Because of this, these studies began by comparing production of AAV1 and AAVrh74 vectors — the latter having a proven track record of manufacturability at the necessary scale for gene therapy (see generally, Shoti, J., et al. Molecular Therapy Methods & Clinical Development, 37; Malhotra, J., et al. Neurology, 700(17_supplement_2), 3838.).The vector production process was divided into three phases — Upstream, Harvest, and Downstream, which are described below in detail.Upstream Process:
[0125] The Upstream Process (as summarized in Figure 1A) began with a vial from the working cell bank being thawed and expanded through a five-stage seed train to provide an inoculum for the suspension production reactor. After a cell growth period in the reactor, a triple transfection was performed using commercially available reagents and 1) pAAV.tMCK. NT3. KAN (SEQ ID NO: 12), containing the expression cassette, 2) either pAAVlRep2Capl. KAN (SEQ ID NO: 10) or pAAVrh74Rep2Capl. KAN (SEQ ID NO: 11), containing the serotype-specific rep and cap genes, and 3) an adenoviral helper plasmid (see, generally Matsushita, T.,et al. (1998). Gene Therapy, 5(7), 938-945.). The culture medium was then supplemented with kanamycin to select for transfected cells. The reactor was held again for the vector production period (approximately 3-7 days, preferably 4 days) before the reactor was harvested as described below.344924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01TABLE 1: Exemplary triple transfection materialsHarvest:
[0126] The Harvest Process (as summarized in Figure IB) began with lysis of the transfected cells to release the virus vector drug substance, which was performed with Polysorbate- 20 following adjustment of the culture pH. A commercially available endonuclease was then added to the lysate to degrade host cell and residual plasmid DNA in the conditioned media. After the lysis, a high concentration salt solution was added to inactive the endonuclease and stabilize the virus vectors.
[0127] Once fully mixed, the reactor harvest was clarified through a series of filters to remove cell debris. The filters were chased with buffer and then purged with air to maximize recovery. The clarified harvest was further processed by tangential flow filtration (TFF), reducing the volume through a concentration step and then removing culture impurities by diafiltration against a salt buffer. Lastly, the retentate was recovered from the TFF system, dispensed, frozen, and stored until needed in the Downstream Process as described below.Downstream Process:
[0128] The Downstream Process (as summarized in Figure 1C) began with thawing and pooling the Harvest Tangential Flow Filtration (TFF) Retentate. The pooled intermediate was filtered and then loaded onto the Capture Chromatography Column filled with an affinity resin. The virus vectors bound to the resin and were eluted under acidic conditions. The elution pool was held under low pH to inactivate potential adventitious viruses before being neutralized.
[0129] Next, a Polishing Chromatography Step was performed to enrich the product stream in full capsids. The affinity pool was diluted and filtered before being loaded onto an anion354924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 exchange (AEX) chromatography column, to which the virus vectors bind. A step in the percentage of Mobile Phase B raised the conductivity to preferentially elute the empty and partially filled virus vectors. A second step further increased the conductivity, to recover full virus vectors. The chromatography was performed at an elevated pH, so the elution pool also required neutralization.
[0130] The neutralized AEX pool was processed through a Virus Retention Filter (VRF) as a precautionary measure to remove any adventitious viruses that may have entered the process. Next, the VRF pool was fed into a TFF step where it was concentrated before a final buffer exchange into the drug substance buffer. A concentrated excipient solution was spiked into the retentate from the Final TFF step to form Formulated Bulk Drug Substance (FBDS). It was then filtered and filled into a bulk storage container. The FBDS was frozen and held until thawed as needed for assay.
[0131] Exemplary batches of AAVrh74. NT3 vector (two 5L batches) and AAV1. NT3 vector (one 10L batch) were produced as described above and assayed. Characteristics assayed included viable cell density (FIG. 2A), as measured on the day of transfection (Day 0) and on the day of harvest (Day 4) using an automated cell culture analyzer, viral genome titer (FIG. 2B), as determined by qPCR on samples collected post-clarification (as described in the Harvest step above), and total viral genomes (FIG. 2C), following generation of FBDS as described above.
[0132] AAVrh74. NT3 vector yield was slightly higher than that of the AAV1. NT3 vector (FIG. 2C). Total yields from 10L FBDS of AAVrh74. NT3 and AAV1. NT3 were 3.53E+14 and 2.54E+14 VG respectively, indicating that the AAVrh74 capsid produced 28% more vector compared to the AAV1 capsid. Similar trends were observed in the VG titer data from an intermediate step post-harvest (FIG. 2B), potentially due to greater cytopathic effects decreasing viability of AAV1. NT3 transfected cells (FIG. 2 A). Consequently, this difference in cytopathic effect seemed to impact viral titers and total viral genomes collected, with AAVrh74 exhibiting notably higher yields in both instances. Taken together, these results indicated that, assuming equivalent function, AAVrh74 vectors would be preferable over AAV 1 in NT3 gene therapy due to higher yield during manufacturing.364924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01TABLE 2: Exemplary materials used during AAV vector productionSeed Train Cell Cnfese Media Gibco™ T ™ isid Pfcsdu an MediumCell Growth Cell Culture Media Gibco™ CTS™ Viral Production Medium„BufferTransfection Reagent Gibcn™ CIS AAV -MAX Traasfeetmn ReagentTrn&sfeebon......................................................................................................................................................................Transfection Booster Gibco™ CIS AAV-MAX BoosterTransfection Enhancer Gibers1*5CTS A AV -MAX EnhancerStage I Filter M Oi ore Clansoive 20 pm Pod Frites-Cto&eation Stage 2 Filter Millistak-;® H<' Pod Fiber with FOHC Media otsse 3 rBter Millipore Ex ■nrass® SHC (RES'! Membratse.b. <te■, O,,.z pm,{. Rail T-Seties Cenasseite withChnesa RESHarvest iTr IFF Membrane Mem,brane,«w••>,kD«a i M«wtuCOCapture Chre fograghy Cfaossitograp&y Resat POROS Ca tureSelect AAVx Affinity ResatPobshing Quoinaio^raphy Claomaiography Resin PORGS 50 HQ Strong Amun Exchange Resin,. „ Planova?< S.. Caarat antnuwn-Reseneta ytras etenratetutr&tioa VRF Rater C «el „hd.ose, Hrrs „How < r-i■gor MembraneFinal Concentration and MtniKros Sam ler Hollow F ber MembraneBuffer ExchangeFilter MsUipa, PVDF Messbrane, 0.22 jrnFiltration and Balk Fill - - -- B5—Db4, Closure Sia e-use Gore® STA-PURE® Flexible Freeze■ContametsExample 2: Comparative potency assays (AAVrh74. NT3 / AAVl. NT3 vectors)
[0133] Having produced that both AAVrh74 and AAV1 vectors, the next step was to test the comparative potency of each in vitro and in vivo. For the in vitro assay, expression potency assay was performed by infecting myoblasts at various MOIs. Cell lysates were harvested at 96 hours post transduction, and 20pg of total protein was resolved by SDS PAGE (4-12% NuPage gel). Proteins were wet transferred on to PVDF membrane, blocked with Tris buffered saline that contained 0.1% Tween and 5% non-fat dry milk and then probed with either a-Neurotrophin-3374924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01(NT3) [1: 500] or a-GAPDH (1:5000) antibodies. The blots were labeled with donkey a-goat-HRP or goat a-rabbit-HRP antibodies (1:1000), respectively and developed with chemiluminescent substrate. Proteins were detected using a BioRad ChemiDoc imaging system. A higher steady state expression of NT3 was observed in cells transduced with AAV1. NT3 as compared to AAVrh74. NT3 at each of the multiplicity of infection (MOI) tested (FIGs. 3 A, 3B).
[0134] Vector potency of the AAV1. NT3 and AAVrh74. NT3 vectors was then further evaluated by intramuscular injection into the gastrocnemius muscle of wild type (C57BL / 6J) mice obtained from The Jackson Laboratory (Bar Harbor, Maine). Mice were 6-8 weeks of age at dosing and were humanely euthanized for sample collection after 4 weeks. Whole blood was collected from a terminal cardiac stick which was processed to obtain serum. Experimental groups included a saline control group as well as treatment groups of AAV1. NT3 and AAVrh74. NT3 at a range of doses. The Human NT-3 DuoSet ELISA Kit from R& D Systems (Minneapolis, MN) was used to quantify the NT-3 protein levels within the collected serum from each animal. NT-3 protein concentration in the serum was read using a BioTek ELx808 Absorbance Microplate Reader (Lonza, Basel, Switzerland) and calculated against a standard curve generated through a four-parameter logistic (4-PL) curve-fit.
[0135] The potency assessment of AAV1. NT3 and AAVrh74. NT3 confirmed that the production of NT-3 protein in a wildtype mouse was detectable by ELISA in the animal’s serum at 4 weeks after treatment for both vectors. An increased dose of each vector produced a reliable trend of a subsequent increase in circulating NT-3 protein levels, suggesting dose dependency. When compared directly, the AAV1. NT3 vector produced higher concentrations of NT-3 protein at 4 weeks post treatment than the AAVrh74. NT3 vector with the same dose, though no significant difference was observed at the highest dose (FIG. 4).
[0136] These results demonstrated that yields from both AAVrh74. NT3 and AAV1. NT3 vectors were sufficient to induce detectable amounts of NT-3 protein in both cells and mice (FIGS.3A and 3B). Notably, detectable levels of circulating NT-3 protein were roughly equivalent following intramuscular injection at the highest dose tested in mice (FIG. 4). Taken together, these results demonstrated that AAVrh74 was the superior vector due to reduced cytopathic effects, greater manufacturability and equivalent potency.384924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01Example 3: In-vivo potency testing of AAVrh74. NT3
[0137] Having determined that AAVrh74. NT3 to be the superior vector for NT3 gene therapy over AAV1. NT3, the next step was to assess biodistribution and best route of administration, comparing intravenous (IV) and intramuscular (IM) injection. C3-PMP mice were administered IM injections at a dose of 3.0xl0nvg bilaterally into the gastrocnemius or with an IV dose of 3.0xl012vg / kg, 3.0xl013vg / kg, or 3.0xl014vg / kg. Animals were dosed at approximately 6 to 8 weeks of age and euthanized and evaluated approximately 10 weeks postdosing (Table 3). Doses were calculated based on linear qPCR titer method and body weights taken on the day of injection. All injections were Q. S. up to 150pL total volume. IM doses were administered into the gastrocnemius muscle with the dose being divided in half between the left and right sides. Animals with calculated dose volumes <100 pL for both left and right doses were Q. S. up to 100 pL total volume with saline (50 pL for muscle injection).TABLE 3: Experimental design for ROA determination
[0138] Biodistribution analysis showed widespread distribution with vector detected in all dosed muscle tissues for the singular IM dose and all IV doses of 3. Ox 1013vg / kg and above (FIG.5A). Circulating vector was readily detectable in the serum in the 3.0xl014vg / kg IV dose, intermittently detectable in the mid-dose IV group and the IM group, and undetectable in the low dose IV group (FIG. 5B). Biodistribution in skeletal muscles, outside of the left gastrocnemius (EGAS), the injection site for IM dosing, was generally similar to the skeletal (FIG. 5C).
[0139] This observation was corroborated by detection of mature NT-3 protein in various tissues. Briefly, samples were homogenized in RIPA buffer with protease and phosphatase inhibitors using a Bullet Blender and centrifuged at 14,000 RPM at approximately 4°C for 10 minutes and the supernatant collected. The concentration of total protein in the supernatant was394924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 determined by BCA. Samples for analysis were diluted to a final concentration of 1 mg / mL, but a concentration of 0.5mg / mL may have been used for samples with low protein concentration and no additional sample available. A standard curve was prepared with a final concentration ranging from 1.95 ng / mL to 62.5 ng / mL. The bottom point of the curve was determined to be outside the range of quantifiable protein and was therefore excluded from analysis, leaving the standard curve range used for analysis as 3.91 ng / mL to 62.5 ng / mL. Prepared samples and recombinant protein standards were denatured at 95°C for 5 minutes. Protein samples, recombinant NT-3 protein standards, and a 2 to 40 kDa biotinylated ladder were loaded into the Jess microplate according manufacturer’s instructions (ProteinSimple, Protein Normalization (PN) Module). Column 1 of the microwell plate was prepared by loading 5 pL of a 2 to 40 kDa biotinylated ladder (row A), 10 pL of blocking agent (rows B-D), 10 pL of streptavidin HRP (row E), and 15pL luminol / peroxide solution (row F). All remaining columns of the microwell plate were prepared by loading 3 pL of sample or recombinant NT-3 protein standard (row A); 10 pL of protein normalization agent for fluorescence detection of total protein content (row B), 10 pL of blocking reagent (row C), 10 pL of anti-NT-3 antibody (MAB267, R& D Systems, 1:2000 dilution; rowD), 10 pL of Donkey antiGoat Secondary HRP Antibody (provided with detection module ready -to-use; row E), and 15 pL luminol / peroxide solution (row F). Each compartment in rows G-I of the microwell plate was loaded with 500 pL of wash buffer. The microwell plate was then run on the Jess instrument per manufacturer’s instructions. Data was analyzed using the Compass for Simple Western software. A fluorescence-based Protein Normalization Assay was utilized as a loading control and for normalization of the protein signal of interest. A sample with >50% error of the total protein area relative to the average PN uncorrected area from the fluorescent PN Channel for all samples was considered a loading error and re-run. Peaks were assigned at ~19 kDa for mature NT-3. These peaks were automatically gated using the “dropped lines” method and the Compass software calculated an area under the curve for each target peak. The area of each standard curve peak was graphed against its known concentration and fitted to a linear regression. The linear regression was then applied to each sample within the standard curve range with an output of ng NT-3 / mL. The value was then converted to ng / mg total protein based on the protein loading concentration. Only mature NT-3 was reported. Acceptance criteria included that 5 peaks were identified in the ladder and that samples were within 50% of the average calculated PN uncorrected area. The standard curve was required to have an R2 value of >0.990. Samples detected above the range of the standard404924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 curve may have been diluted and rerun; samples falling below the range of the standard curve were designated BLQ.
[0140] Expression of mature NT-3 was observed in the RGAS for the IM dosed group, but not in the heart muscle tissues (FIGs. 6A, 6B). Expression of mature NT-3 was generally low or undetectable across muscle tissues in the low-dose and mid-dose IV groups, and was undetectable in the RGAS for 4 of 10 animals in the high-dose IV group.
[0141] Additionally, circulating NT-3 was evaluated longitudinally in serum using MSD. Briefly, Circulating NT-3 was assessed in serum using an R-Plex kit from MSD (MSD K1519VR). Briefly, the capture antibody was coupled with the linker according to the manufacturer’s instructions. The plate was coated with the provided antibody for 1 hour at room temperature. The plate was washed 3 times with wash buffer prior to loading samples. A standard curve was prepared with a range between 1.221 to 5000 pg / mL NT-3 standard. Samples were primarily diluted 1:6 and loaded at 25 pL / well, although other dilutions may have been used as necessary. A negative control (naive C57BL / 6J serum diluted 1:6) and positive control (naive C57BL / 6J serum diluted 1:6 and spiked with 200 pg / mL recombinant NT-3 protein; recombinant NT-3 provided by the kit) were additionally included on the plate. Samples were incubated for 1 hour, then the plate was washed 3 times with wash buffer. The detection antibody (Sulfo-tag Human NT-3) was diluted according to the kit instructions and incubated for 1 hour. The plate was washed 3 times with wash buffer, then 150 pL read buffer were added to each well. The plate was then read on the MESO QuickPlex SQ 120MM. The assay was considered valid if it met the following acceptance criteria: the R2 of the standard curve must be > 0.900, spike control recovery must be between 80% and 120%, duplicate wells must have %CV<20%, and the negative control MSD signal mean must be below 300 RLU. The data was analyzed using the Discovery Workbench software. The software calculates the average concentration of each sample based on a four-parameter logistic (4-PL) standard curvefit and the dilution factor of the sample.
[0142] Values for the IM injection group were generally similar to those from the mid-dose IV group, ranging on average from 36% to 134% of the mid-dose IV group value across the different time points (FIG. 7). The low-dose IV group resulted in much lower levels of NT-3 as compared to the IM injection group, typically between 3% and 10% of the value observed in the IM group. Likewise, the high-dose IV group resulted in significantly higher levels of NT-3 as compared to the IM injection group at all but one time point, ranging from 15x to 67x the IM value.414924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01Values within a dose or ROA generally peaked around day 14 and remained consistent longitudinally.
[0143] Taken together, these results indicated that bilateral vector delivery of a 3.0* 1011vg IM dose of AAVrh74. NT3 into the gastrocnemius can result in similar vector biodistribution in target tissues as well as similar circulating NT-3 levels compared to dosing 3.0* 1013vg / kg by IV. However, IM dosing appears advantageous due to the ability to de-target the heart and liver relative to skeletal muscle. These data additionally demonstrate potency of the test article through sustained serum NT-3 levels observed out to 10 weeks post-dosing regardless of the route of administration.
[0144] It is understood that the examples and aspects described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.SEQUENCE TABLETable 4: Exemplary sequences of the present disclosure424924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01434924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01444924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01454924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01464924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01474924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01484924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01494924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01504924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01514924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01524924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01534924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01544924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01554924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01Additional Embodiments
[0145] Embodiment 1. A recombinant adeno-associated virus (rAAV) particle comprising a payload nucleotide sequence which comprises the payload nucleotide sequence as set forth in SEQ ID NO: 8 and an AAVrh74 capsid protein comprising the amino acid sequence set forth in SEQ ID NO: 9.
[0146] Embodiment 2. A rAAV particle comprising a capsid protein and a payload nucleotide sequence, wherein the payload nucleotide sequence comprises: (i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1; (ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2; (iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3; (iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5; (v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and (vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7, and wherein the capsid protein comprises an AAVrh74 capsid protein as set forth in SEQ ID NO: 9, or a variant thereof.564924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01
[0147] Embodiment 3. The rAAV particle of embodiment 2, wherein the payload nucleotide sequence has a nucleotide sequence at least 95% sequence identity to SEQ ID NO: 8.
[0148] Embodiment 4. The rAAV particle of embodiment 2, wherein the payload nucleotide sequence has a nucleotide sequence at least 99% sequence identity to SEQ ID NO: 8.
[0149] Embodiment 5. The rAAV particle of embodiment 2, wherein the payload nucleotide sequence has the nucleotide sequence set forth in SEQ ID NO: 8.
[0150] Embodiment 6. The rAAV particle of any one of embodiments 1 to 5, which is formulated with a pharmaceutically acceptable carrier.
[0151] Embodiment 7. An expression cassette comprising the nucleotide sequence set forth in SEQ ID NO: 8.
[0152] Embodiment 8. An expression cassette comprising a payload nucleotide sequence which comprises: (i) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2; (ii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3; (iii) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5; and (iv) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6.
[0153] Embodiment 9. A vector comprising the expression cassette of embodiment 7.
[0154] Embodiment 10. A vector comprising the expression cassette of embodiment 8.
[0155] Embodiment 11. The vector of embodiment 9 or 10, wherein the vector is an AAV vector.
[0156] Embodiment 12. The vector of embodiment 10 or 11, which further comprises a nucleotide sequence comprising a first inverted terminal repeat (ITR) and a second ITR.
[0157] Embodiment 13. The vector of embodiment 12, wherein the first ITR is at the 5' of the payload nucleotide sequence and a second ITR is at the 3' of the payload nucleotide sequence.
[0158] Embodiment 14. The vector of embodiment 12 or 13, wherein the first and the second ITR are derived from a same or from different serotypes.
[0159] Embodiment 15. The vector of embodiment 14, wherein the serotype of one or both of the ITRs is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAVrhlO, AAVrh74, AAV11, or AAV12 serotype.
[0160] Embodiment 16. The vector of embodiment 15, wherein the first ITR comprises a nucleotide sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at574924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1.
[0161] Embodiment 17. The vector of embodiment 15 or 16, wherein the second ITR comprises a nucleotide sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 7.
[0162] Embodiment 18. The vector of any one of embodiments 12 to 17, wherein the vector further comprises a nucleotide sequence encoding a selectable marker.
[0163] Embodiment 19. A pharmaceutical formulation comprising the rAAV particle of any one of embodiments 1-6, the expression cassette of embodiment 7 or 8, the vector of any one of embodiments 8-18, or any combination thereof and at least one pharmaceutically acceptable carrier.
[0164] Embodiment 20. A nucleic acid comprising a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO: 12 (pAAV.tMCK. NT3. KAN).
[0165] Embodiment 21. The nucleic acid of embodiment 20, wherein the nucleotide sequence has at least 99% sequence identity to SEQ ID NO: 12.
[0166] Embodiment 22. The nucleic acid of embodiment 21, wherein the nucleotide sequence comprises the sequence set forth in SEQ ID NO: 12.
[0167] Embodiment 23. A cell comprising the nucleic acid of any one of embodiments 20-22.
[0168] Embodiment 24. The cell of embodiment 23, wherein the cell comprises a packaging cell.
[0169] Embodiment 25. The cell of embodiment 24, wherein the cell comprises a HeLa cell, a human fetal kidney cell (HEK293 cell), a PerC6 cell, a human fetal fibroblast cell (MRC-5 cell), a human fetal fibroblast cell (WI-38 cell), a monkey kidney cell (Vero cell), a rhesus fetal lung cell (FRhL-2 cell), or any combination thereof.
[0170] Embodiment 26. A method of producing an infectious recombinant AAV (rAAV) particle, the method comprising contacting the nucleic acid of any one of embodiments 20-25 to a mammalian cell.
[0171] Embodiment 27. The method of embodiment 26, wherein the mammalian cells is simultaneously contacted with: (i) a capsid-specific AAV rep / cap plasmid; and (ii) an adenoviral584924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 helper plasmid, wherein the mammalian cell is subsequently placed under selection conditions for a period of about 1-7 days.
[0172] Embodiment 28. The method of embodiment 27, wherein the capsid-specific AAV rep / cap plasmid is at least 90% identical to the nucleotide sequence of SEQ ID NO: 11.
[0173] Embodiment 29. The method of embodiment 27, wherein the capsid-specific AAV rep / cap plasmid is at least 95% identical to the nucleotide sequence of SEQ ID NO: 11.
[0174] Embodiment 30. The method of embodiment 27, wherein the capsid-specific AAV rep / cap plasmid is identical to the nucleotide sequence of SEQ ID NO: 11.
[0175] Embodiment 31. The method of embodiment 27, wherein the mammalian cell is placed under selection conditions for a period of about 4 days.
[0176] Embodiment 32. The method of embodiments 26-31, wherein the mammalian cell is a human cell.
[0177] Embodiment 33. The method of embodiments 26-32, further comprising:(i) lysing the population of cells to obtain a lysate;(ii) subjecting the lysate to tangential flow filtration (TFF) to generate a retentate;(iii) loading the retentate in a capture chromatography column;(iv) eluting viral particles with an acidic wash;(v) subjecting the viral particles to anion-exchange chromatography (AEX) and elution;and(vi) a final filtration to generate a bulk drug substance of rAAV particles.
[0178] Embodiment 34. A method of increasing the amount of functional neurotrophin-3 protein in a cell comprising contacting the cell with the rAAV particle of any one of claims 1-6, the expression cassette of claim 7 or 8, the vector of any one of claims 9-18, the pharmaceutical formulation of claim 19, or any combination thereof.
[0179] Embodiment 35. The method of embodiment 34, wherein the cell comprises a muscle cell.594924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01
[0180] Embodiment 36. The method of embodiment 34, wherein the cell comprises a neuron.
[0181] Embodiment 37. The method of any one of embodiments 34-36, wherein the cell comprises a human cell.604924-7776-8874.5
Claims
1. Atty Docket No. 140056-10122025-039-02; 8216. WO01CLAIMS1. A recombinant adeno-associated virus (rAAV) particle comprising a payload nucleotide sequence which comprises the payload nucleotide sequence as set forth in SEQ ID NO: 8 and an AAVrh74 capsid protein comprising the amino acid sequence set forth in SEQ ID NO: 9.
2. A rAAV particle comprising a capsid protein and a payload nucleotide sequence, wherein the payload nucleotide sequence comprises:(i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1;(ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5;(v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and(vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7, andwherein the capsid protein comprises an AAVrh74 capsid protein as set forth in SEQ ID NO: 9, or a variant thereof.
3. The rAAV particle of claim 2, wherein the payload nucleotide sequence has a nucleotide sequence at least 95% sequence identity to SEQ ID NO: 8.
4. The rAAV particle of claim 2, wherein the payload nucleotide sequence has a nucleotide sequence at least 99% sequence identity to SEQ ID NO: 8.
5. The rAAV particle of claim 2, wherein the payload nucleotide sequence has the nucleotide sequence set forth in SEQ ID NO: 8.
6. The rAAV particle of any one of claims 1 to 5, which is formulated with a pharmaceutically acceptable carrier.614924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO017. An expression cassette comprising the nucleotide sequence set forth in SEQ ID NO: 8.
8. An expression cassette comprising a payload nucleotide sequence which comprises:(i) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(ii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iii) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5; and(iv) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6.
9. A vector comprising the expression cassette of claim 7.
10. A vector comprising the expression cassette of claim 8.
11. The vector of claim 9 or 10, wherein the vector is an AAV vector.
12. The vector of claim 10 or 11, which further comprises a nucleotide sequence comprising a first inverted terminal repeat (ITR) and a second ITR.
13. The vector of claim 12, wherein the first ITR is at the 5' of the payload nucleotide sequence and a second ITR is at the 3' of the payload nucleotide sequence.
14. The vector of claim 12 or 13, wherein the first and the second ITR are derived from a same or from different serotypes.
15. The vector of claim 14, wherein the serotype of one or both of the ITRs is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAVRH10, AAVRH74, AAV11, or AAV12 serotype.
16. The vector of claim 15, wherein the first ITR comprises a nucleotide sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1.624924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO0117. The vector of claim 15 or 16, wherein the second ITR comprises a nucleotide sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 7.
18. The vector of any one of claims 12 to 17, wherein the vector further comprises a nucleotide sequence encoding a selectable marker.
19. A pharmaceutical formulation comprising the rAAV particle of any one of claims 1-6, the expression cassette of claim 7 or 8, the vector of any one of claims 8- 18, or any combination thereof and at least one pharmaceutically acceptable carrier.
20. A nucleic acid comprising a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO: 12.
21. The nucleic acid of claim 20, wherein the nucleotide sequence has at least 99% sequence identity to SEQ ID NO: 12.
22. The nucleic acid of claim 21, wherein the nucleotide sequence comprises the sequence set forth in SEQ ID NO: 12.
23. A cell comprising the nucleic acid of any one of claims 20-22.
24. The cell of claim 23, wherein the cell comprises a packaging cell.
25. The cell of claim 24, wherein the cell comprises a HeLa cell, a human fetal kidney cell (HEK293 cell), a PerC6 cell, a human fetal fibroblast cell (MRC-5 cell), a human fetal fibroblast cell (WI-38 cell), a monkey kidney cell (Vero cell), a rhesus fetal lung cell (FRhL-2 cell), or any combination thereof.
26. A method of producing a recombinant AAV (rAAV) particle, the method comprising contacting the nucleic acid of any one of claims 20-22 to a mammalian cell.
27. The method of claim 26, wherein the mammalian cells is simultaneously contacted with:(i) a capsid-specific AAV rep / cap plasmid; and634924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01(ii) an adenoviral helper plasmid,wherein the mammalian cell is subsequently placed under selection conditions for a period of about 1-7 days.
28. The method of claim 27, wherein the capsid-specific AAV rep / cap plasmid is at least 90% identical to the nucleotide sequence of SEQ ID NO: 11.
29. The method of claim 27, wherein the capsid-specific AAV rep / cap plasmid is at least 95% identical to the nucleotide sequence of SEQ ID NO: 11.
30. The method of claim 27, wherein the capsid-specific AAV rep / cap plasmid is identical to the nucleotide sequence of SEQ ID NO: 11.
31. The method of claim 27, wherein the mammalian cell is placed under selection conditions for a period of about 4 days.
32. The method of claims 27-31, wherein the mammalian cell is a human cell.
33. The method of claims 27-32, further comprising:(vii) lysing the population of cells to obtain a lysate;(viii) subjecting the lysate to tangential flow filtration (TFF) to generate a retentate;(ix) loading the retentate in a capture chromatography column;(x) eluting viral particles with an acidic wash;(xi) subjecting the viral particles to anion-exchange chromatography (AEX) and elution;and(xii) a final filtration to generate a bulk drug substance of rAAV particles.
34. A method of increasing the amount of functional neurotrophin-3 protein in a cell comprising contacting the cell with the rAAV particle of any one of claims 1-6, the expression644924-7776-8874.5Atty Docket No. 140056-10122025-039-02; 8216. WO01 cassette of claim 7 or 8, the vector of any one of claims 9-18, the pharmaceutical formulation of claim 19, or any combination thereof.
35. The method of claim 34, wherein the cell comprises a muscle cell.
36. The method of claim 34, wherein the cell comprises a neuron.
37. The method of any one of claims 34-36, wherein the cell comprises a human cell.654924-7776-8874.5
